Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

Molecular Immunology

Volumn 36, Issue 7, 1999, Pages 433-446

  McCall, A M ^a   Adams, G P ^a   Amoroso, A R ^a   Nielsen, U B ^b   Zhang, L ^a   Horak, E ^a   Simmons, H ^a   Schier, R ^b   Marks, J D ^b   Weiner, L M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Bispecific; CD16; HER2 neu phage display library; scFv

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; EPITOPE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOLYSIS; EPITOPE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION;

EID: 0032783692     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00057-7     Document Type: Article

References (37)

1. 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res. 49:1989;1707-1711.
2. Adams G.P., McCartney J.E., Tai M-S., Oppermann H., Huston J.S., Stafford W.F., Bookman M.A., Fand I., Houston L.L., Weiner L.M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single chain Fv. Cancer Res. 53:1993;4026-4034.
3. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., Weiner L.M. Increased affinity leads to improve selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:1998;485-490.
4. Deo Y.M., Graziano R.F., Repp R., van de Winkel J.G.J. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today. 18:1997;127-135.
5. de Vries E., Koene H.R., Vossen J.M., Gratama J.W., von dem Borne A.E.G.Kr, Waaijer J.L.M., Haraldsson A., de Haas M., van Tol M.J.D. Identification of an unusual Fcγ receptor IIIa on natural killer cells in a patient with recurrent infections. Blood. 88:1996;3022-3027.
6. de Wildt R.M.T., Finnern R., Ouwehand W.H., Griffiths A.D., van Venrooij W.J., Hoet R.M.A. Characterization of human variable domain antibody fragments against the U1 RNA-associated A protein, selected from a synthetic and a patient-derived combinatorial V gene library. Eur. J. Immunol. 26:1996;629-639.
7. Fanger M.W., Shen L., Graziano R.F., Guyre P.M. Cytotoxicity mediated by human Fc receptors for IgG. Immunology Today. 10:1989;92-99.
8. Graziano R.F., Tempest P.R., White P., Keler T., Deo Y., Ghebremariam H., Coleman K., Pfefferkorn L.C., Fanger M.W., Guyre P.M. Construction and characterization of a humanized anti-γ-Ig receptor Type I (FcγRI) monoclonal antibody. J. Immunol. 155:1995;4996-5002.
9. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., Allison T.J., Prospero T.D., Hoogenboom H.R., Nissim A., Cox J.P.L., Harrison J.L., Zaccolo M., Gherardi E., Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
10. Hibbs M.L., Tolvanen L.M., Carpén O. Membrane-proximal Ig-like domain of FcγRIII (CD16) contains residues critical for ligand binding. J. Immunol. 152:1994;4466-4474.
11. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19:1991;4133-4137.
12. Jawahar S., Moody C., Chan M., Finberg R., Geha R., Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16 II). Clin. Exp. Immunol. 103:1996;408-413.
13. Jönsson U., Fägerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Löfås S., Persson B., Roos H., Rönnberg I., Sjölander S., Stenberg E., Ståhlberg R., Urbaniczky C., Östlin H., Malmqvist M. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 11:1991;620-627.
14. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods. 145:1991;229-240.
15. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
16. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
17. Meares C.F., McCall M.J., Reardan D.T., Goodwin D.A., Diamanti P.I., McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142:1984;68-78.
18. Michon J., Perdereau B., Brixy F., Moutel S., Fridman W-H., Teillaud J-L. in vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-FcγRI (CD64) bispecific antibody. Eur. J. Cancer. 31A:1995;631-636.
19. 2 bispecific monoclonal antibody. Br. J. Cancer. 72:1995;928-933.
20. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., Winter G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13:1994;692-698.
21. Ravetch J.V., Perussia B. Alternative membrane forms of FcγRIII (CD16) on human NK cells and neutrophils: cell-type specific expression of two genes which differ in single nucleotide substitutions. J. Exp. Med. 17:1989;481-497.
22. Ravetch J.V., Siebenlist U., Korsmeyer S., Waldmann T., Leder P. Structure of the human immunoglobulin μ locus: characterization of embryonic and rearranged J and D genes. Cell. 27:1981;583-591.
23. Schier R., Marks J.D., Wolf E.J., Apell G., Wong C., McCartney J.E., Bookman M.A., Huston J.S., Houston L.L., Weiner L.M., Adams G.P. in vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1:1995;73-81.
24. Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C., Marks J.D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:1996;551-567.
25. Shalaby M.R., Carter P., Maneval D., Giltinan D., Kotts C. Bispecific HER2×CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin. Immunol. Immunopath. 74:1995;185-192.
26. Steplewski Z., Lubeck M.D., Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 221:1983;865-867.
27. van Ojik H.H., Repp R., Groenewegen G., Valerius T., van de Winkel J.G.J. Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI×anti-HER2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer. Cancer Immunol. Immunother. 45:1997;207-209.
28. Tamm A., Schmidt R.E. The binding epitopes of human CD16 (FcγRIII) monoclonal antibodies. Implications for ligand binding. J. Immunol. 157:1996;1576-1581.
29. H segments with different hypervariable loops. J. Mol. Biol. 227:1992;776-798.
30. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., Graziano R., Fisher J.L., Meyer L., Mrozek-Orlowski M., Wardwell K., Guyre V., Morley T.L., Arvizu C., Fanger M.W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncology. 13:1995;2281-2292.
31. van de Winkel J.G.J., Bast B., de Gast G.C. Immunotherapeutic potential of bispecific antibodies. Immunol. Today. 18:1997;562-564.
32. van Dijk J., Zegveld S.Th, Fleuren G.J., Warnaar S.O. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int. J. Cancer. 48:1991;738-743.
33. Vasicek T.J., Leder P. Structure and expression of the human immunoglobulin λ genes. J. Exp. Med. 172:1990;609-620.
34. Weiner L.M., Alpaugh R.K., Amoroso A.R., Adams G.P., Ring D.B., Barth M.W. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human FcγRIII. Cancer Immunol. Immunother. 42:1996;141-150.
35. Weiner L.M., Clark J.I., Ring D.B., Alpaugh R.K. Clinical development of 2B1 a bispecific murine monoclonal antibody targeting c-erbB-2 and FcγRIII. J. Hematother. 4:1995;453-456.
36. Weiner L.M., Holmes M., Adams G.P., LaCreta F., Watts P., de Palazzo G. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53:1993;94-100.
37. λ gene segments. Eur. J. Immunol. 23:1993;1456-1461.